Andrew Hastie

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

M. Ranson, J. Schellens, F. André, 2013 .

Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors

M. Ranson, J. Schellens, F. André, 2013 .

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)

Chong-Jen Yu, A. Schuind, J. Díez-Domingo, 2020, Open Forum Infectious Diseases.

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

M. Ranson, J. Schellens, K. Tamura, 2013 .

Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

M. Ranson, J. Schellens, K. Tamura, 2013 .

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

T. Mrkvan, T. Schwarz, L. Rombo, 2020, The Journal of infectious diseases.